Antibody Core

抗体核心

• 批准号: 10549477
• 负责人: Ali Hassan Ellebedy
• 金额: $ 20.85万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-21 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10549477
• 关键词: 2019-nCoV; Acceleration; Achievement; Activities of Daily Living; Animal Model; Antibodies; Antigens; B-Lymphocytes; Bacillus anthracis; Binding; Blood; Bone Marrow; COVID-19; COVID-19 pandemic; COVID-19 therapeutics; Cell Separation; Chronic; Circulation; Clinical; Clinical Trials; Clostridium difficile; Collaborations; Coronavirus; Coronavirus Infections; Coronavirus spike protein; Development; Diagnostic tests; Dose; Enterotoxins; Environment; Epitope Mapping; Epitopes; FDA approved; Generations; Goals; Human; Humoral Immunities; Immune; Immune response; Immunity; Immunize; Immunologics; Infection; Inflammatory; Institution; Knowledge; Life; Malignant Neoplasms; Maps; Metabolic Diseases; Methodology; Middle East Respiratory Syndrome Coronavirus; Moderna COVID-19 vaccine; Monoclonal Antibodies; Mus; Neurons; Nucleosides; Peripheral Blood Mononuclear Cell; Pfizer-BioNTech COVID-19 vaccine; Pharmaceutical Preparations; Pre-Clinical Model; Productivity; Proteins; Public Health; Publishing; RNA vaccination; RNA vaccine; Recombinants; Recording of previous events; Research; Research Project Grants; Resources; Respiratory syncytial virus; SARS coronavirus; SARS-CoV-2 antibody; SARS-CoV-2 spike protein; SARS-CoV-2 variant; Sarbecovirus; Scientist; Screening procedure; Specificity; Specimen; Structure; Technology; Therapeutic; Time; United States; Universities; Vaccination; Vaccine Design; Vaccinee; Vaccines; Variant; Viral; Virus; Washington; Work; betacoronavirus; betacoronavirus vaccine; cohort; coronavirus vaccination; coronavirus vaccine; cross reactivity; design; efficacy evaluation; efficacy testing; flexibility; future pandemic; human coronavirus; human disease; human model; human monoclonal antibodies; imprint; improved; insight; lymph nodes; multidisciplinary; murine monoclonal antibody; natural antibodies; neutralizing antibody; novel; pathogenic microbe; programs; response; risk mitigation; single cell technology; single-cell RNA sequencing; synergism; technology platform; vaccine candidate; vaccine development; variants of concern; ward

The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-lasting Immunity to Coronaviruses (PLUTO)” proposes a comprehensive research plan towards designing pan-sarbecovirus and pan-betacoronavirus vaccines with broad protection by applying in-depth B cell characterization in the context of coronavirus immune histories imprinted by successive vaccinations and/or infections. Two complementary research projects will establish correlates of robust, durable and protective coronavirus humoral immunity (Project 1) as well as design and test efficacy of viral variant-proof pan-sarbecovirus and pan-betacoronavirus vaccines (Project 2). The Cores will synergize with the two research projects to support the successful completion of the research aims. The Administrative Core will manage the consortium, coordinate cross-project activities, and create the structure and environment needed to accomplish PLUTO’s goals. The Antibody Core will develop large panels of recombinant monoclonal antibodies (mAbs) against coronavirus spike proteins to define specificity and breath of immune responses elicited by coronavirus infections and/or vaccinations in humans and animal models. The Animal Model Core will provide a central resource with approvals, facilities, and expertise to assess efficacy of broadly cross-reactive coronavirus antibodies and vaccines in robust pre-clinical models against a spectrum of coronaviruses, including Select Agents. A multidisciplinary team of scientists from five institutions who have an outstanding track record of working collaboratively will conduct the proposed studies. The Research Projects will collaborate with each other and with the Antibody and Animal Model Cores, coordinated by the Administrative Core. The integrated and synergistic activities across Projects and Cores will drive the successful completion of the program project’s ambitious research agenda, enabling achievement of the long-term PLUTO goal of developing variant-proof pan-sarbecovirus and pan-betacoronavirus vaccines. These findings will contribute to curbing the current SARS-CoV-2 pandemic and mitigate the risk of future pandemics with coronaviruses.

SARS-CoV-2大流行是一场特殊的公共卫生危机，突出表明需要做出更好的努力